


# Biologics and Vaccines



The National Biologics Facility (NBF) enables Australian researchers to identify and translate their biomedical research discoveries, bridging the gap between early-stage development, testing and clinical supply for next-gen therapeutic candidates.

Supported by Therapeutic Innovation Australia (TIA), NBF is a network of facilities, platform technologies and subject matter experts focused on the development of your biotherapeutic from discovery through to the scale-up and manufacturing of clinically-relevant material.



National  
Biologics  
Facility



THERAPEUTIC  
INNOVATION  
AUSTRALIA

ENABLED BY:

**NCRIS**

National Research  
Infrastructure for Australia  
An Australian Government Initiative

CONTACT:

T: (07) 3735 4433

E: [info@therapeuticinnovation.com.au](mailto:info@therapeuticinnovation.com.au)

Level 14, 330 Collins Street,  
Melbourne VIC 3000

[www.therapeuticinnovation.com.au/biologics](http://www.therapeuticinnovation.com.au/biologics)



## The National Biologics Facility

NBF provides key infrastructure maintained under phase-appropriate quality systems to support therapeutic discovery, from screening of antibody libraries and production of high-quality recombinant proteins as small-molecule drug targets, through to novel, engineered biologics, vaccine antigens and diagnostic reagents

Collectively, the three NBF nodes provide specialist advice across the spectrum of biopharmaceutical development supporting the translation through to proof of concept, pre-clinical and clinical supply. Expert staff draw upon decades of manufacturing expertise and access to a range of platforms, including:

- NIBRT's bioprocessing short courses in a simulated cGMP environment
- Advanced protein engineering and *in vitro* display technologies for antibody discovery
- Cell line development and high throughput mammalian clonal selection
- Proven record of development programs through to Phase I cGMP
- Advanced protein bioanalytics – stability studies and characterisation of variants
- Access to high-end mass spectrometry including via BioPlatforms Australia
- Expertise with antibody drug conjugates and chemical bioconjugation techniques
- Mammalian focus with expertise in viral, microbial and insect systems to 200L scale
- New cGMP facility to 200L scale with form and fill capabilities, complete QC testing and release (anticipated TGA inspection Dec 2021).

The experienced scientists at NBF can assist with all aspects of development of novel biologics and have strong links and track records in tech transferring to local CROs and CMOs to assist with scale-up to larger volumes. Whether you need assistance with discovery, development or production, Australia's NBF is at your service.

## NBF Partners



### NBF, Queensland Node



### NBF, New South Wales Node



### NBF, Victoria Node



#### CONTACT:

To find out more about the National Biologics Facility, visit:

[www.nationalbiologicsfacility.com](http://www.nationalbiologicsfacility.com)

or email us at [info@therapeuticinnovation.com.au](mailto:info@therapeuticinnovation.com.au).